Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting...
By Ankika Biswas and Bansari Mayur Kamdar (Reuters) -European shares edged higher on Monday after a strong week driven by aggressive bets on interest rate cuts, while...
JEFFERSON CITY - In a landmark legal decision late Friday, a Missouri Circuit Court ruled that Bayer AG (ETR:BAYGN)'s Monsanto (NYSE:MON) must pay a collective sum...
By Joan Faus BARCELONA (Reuters) -Colombian pop star Shakira on Monday reached a settlement with prosecutors to avoid a trial in Barcelona over charges she failed to pay 14.5...
Sharecast - Bayer (ETR:BAYGN) aborted its phase III trial on asundexian early on the back of a recommendation from the Independent Data Monitoring Committee, which concluded the...
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study early after asundexian showed inferiority to Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer...
Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial...
LEVERKUSEN - Bayer AG (ETR:BAYGN) has ceased its phase III asundexian trial early based on the recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC...
Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug...
The German pharma and agriculture company stopped the main study of its top experimental medicine due to a lack of efficacy and lost a key US trial against its weed killer Roundup.